SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-037811
Filing Date
2020-08-06
Accepted
2020-08-06 16:33:42
Documents
14
Period of Report
2020-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eidx-8k_20200806.htm   iXBRL 8-K 40984
2 EX-99.1 eidx-ex991_6.htm EX-99.1 349561
3 GRAPHIC g4n3scshomv2000001.jpg GRAPHIC 2631
  Complete submission text file 0001564590-20-037811.txt   543070

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eidx-20200806.xsd EX-101.SCH 5756
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eidx-20200806_lab.xml EX-101.LAB 20227
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eidx-20200806_pre.xml EX-101.PRE 12069
7 EXTRACTED XBRL INSTANCE DOCUMENT eidx-8k_20200806_htm.xml XML 3673
Mailing Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104
Business Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104 650-391-9740
Eidos Therapeutics, Inc. (Filer) CIK: 0001731831 (see all company filings)

IRS No.: 463733671 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38533 | Film No.: 201082262
SIC: 2834 Pharmaceutical Preparations